Ongoing Clinical Trials for Peripheral Artery Thrombosis
There is currently 1 ongoing clinical trial for peripheral artery thrombosis, investigating the use of antiplatelet medications to prevent serious cardiovascular events in patients who have undergone procedures to open blocked arteries in the legs. This trial is taking place in the Netherlands and compares single versus dual antiplatelet therapy.
Clinical trial locations
Study on the Effect of Clopidogrel and Acetylsalicylic Acid on Reducing Heart and Blood Vessel Events in Patients with Peripheral Arterial Disease
This clinical trial is examining whether combining two medications that prevent blood clots is more effective than using just one in patients with peripheral arterial disease who have had a procedure to open blocked blood vessels in their legs.
Main inclusion criteria:
- Patients must be 45 years old or older
- Patients must have blockages in specific arteries of the legs (iliac, femoropopliteal, or below-the-knee arteries)
- Patients must have at least one TASC lesion, which is a type of blockage in the arteries
- Patients must fall into Rutherford classes 1-6, categories that describe the severity of symptoms, and require a procedure to open up the arteries
- The blockages must be suitable for treatment with procedures such as percutaneous transluminal angioplasty (a procedure to open blocked arteries), hybrid procedures (combining surgery with other treatments), or reintervention within 2 months
- Patients must understand the study and provide written informed consent
Main exclusion criteria:
- Patients with other serious health conditions that could interfere with the study
- Patients unable to follow study procedures or attend follow-up visits
- Patients currently participating in another clinical trial
- Patients who have had a recent heart attack or stroke
- Patients with severe liver or kidney disease
- Pregnant or breastfeeding patients
- Patients with a known allergy to the study medications
- Patients with a history of bleeding disorders
- Patients who have had recent major surgery
- Patients with uncontrolled high blood pressure
Focus and goal of the trial:
The trial aims to determine whether using two antiplatelet medications together (dual antiplatelet therapy) is more effective than using one medication alone (single antiplatelet therapy) in reducing serious health events such as heart attacks, strokes, repeat procedures, or amputations. Participants will be randomly assigned to receive either clopidogrel alone or clopidogrel combined with acetylsalicylic acid (aspirin). The study will last for up to 12 months, during which researchers will monitor participants for cardiovascular events, complications, and side effects such as bleeding.
Investigational drugs:
The trial is testing clopidogrel and acetylsalicylic acid (commonly known as aspirin). Clopidogrel is a medication that makes the blood less sticky, helping to prevent harmful blood clots that can lead to heart attacks or strokes. It is taken orally as a 75 mg tablet once daily. Acetylsalicylic acid is also used to prevent blood clots and is taken as an 80 mg tablet once daily. Together, these medications form what is known as dual antiplatelet therapy. The study will compare this combination treatment against using clopidogrel alone to see which approach is more effective in preventing serious cardiovascular and limb-related events in patients with peripheral arterial disease.
Summary
Currently, there is one clinical trial investigating treatment options for patients with peripheral artery thrombosis who have undergone procedures to restore blood flow in their legs. The trial is being conducted in the Netherlands and focuses on comparing the effectiveness of single versus dual antiplatelet therapy using clopidogrel and acetylsalicylic acid. The study aims to provide valuable information about which treatment approach offers better protection against serious cardiovascular events, repeat procedures, and amputations while also monitoring for bleeding complications. Patients aged 45 and older with specific types of arterial blockages in their legs may be eligible to participate in this research.
